A prospective, cohort study assessing the SARS-COV-2 vaccine immunogenicity in PLWH in the Netherlands
Latest Information Update: 08 Sep 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 02 Aug 2022 Results presented at the 24th International AIDS Conference
- 29 Mar 2022 New trial record
- 16 Feb 2022 Primary endpoint (Anti-SARS-CoV-2 IgG response (Liaison Trimeric Spike IgG in BAU/ml) measured 4-6 weeks after vaccination with one of the 2 mRNA vaccines in PLWH versus controls) has been met according to the results presented at the 29th Conference on Retroviruses and Opportunistic Infections